Audit: QRS - Solubilized Keratin for Health & Longevity
Audit conducted on 13/08/2026 07:14 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 85 |
| Failed | 0 |
| N/A | 8 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Every populated span traces to ER text: protocol cells to ER Therapeutic Protocol, time cells to Practical Considerations / Therapeutic Protocol, benefits/risks to the tiered ER headings, monitoring rows to the ER biomarker table. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “durability beyond that is unknown” (time_3_sub) mirrors ER line 173; “Almost all trials were funded by the sellers and none reproduced independently” mirrors ER Conclusion line 478. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Pregnancy/lactation and under-18 remain in the Contraindications gate, not the Key Interactions gate; no tier is upgraded or downgraded relative to the ER. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications come only from the ER “Populations who should avoid” list; Key Interactions only from the ER interaction bullets; no Benefit- or Risk-Modifying Factor is surfaced as a gate. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, author names, NCT identifiers or brand names (Cynatine, Roxlor, BCF, Kera-Diet) appear anywhere in the QRS body. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | The ER’s attribution “Practitioners in functional and cosmetic dermatology” is dropped rather than replaced; no new attribution is added. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | The ER’s sceptical framing (sponsor funding, no independent replication, cosmetic not life-extending) is carried through at_a_glance and the protocol subs. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Objective and data-driven throughout; the actionable protocol, time-to-effect and monitoring panels give the reader a workable path without overselling. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Statements describe what trials did and found (“Split dosing is the studied pattern”, “The endpoint that trials actually moved”) rather than issuing orders. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperative clinical instructions; the footer disclaimer is the unmodified template text. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No occurrence of “recommend”, “advise”, “should” in the QRS voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the body. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are ER-sourced and expanded where the ER expands them (e.g. “Thyroid-stimulating hormone (TSH)”, “Estimated glomerular filtration rate (eGFR)”). |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Benefit and risk tiers are single semicolon-separated clause lists; gate items are single facts. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed: no “you”/”your” in the rendered body. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | The sheet assumes willingness to baseline-test, track shed counts and run a 90-day trial. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | An 11-marker baseline panel, monthly nail counts and fixed-lighting photography are all retained rather than trimmed for convenience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Depth of monitoring and interaction detail exceeds general-population framing. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | at_a_glance names the sponsor-funding limitation and the “cosmetic, not life-extending” distinction, which is the point that matters most to a longevity-oriented reader. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “anti-aging” does not appear; the header uses “Health & Longevity” and at_a_glance uses “life-extending”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | “capsules”, “gastrointestinal intolerance”, “immunoassays”, “shedding” — all ER register; no colloquialisms. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed strings byte-identical to core/qrs/QRS.html (lines 437, 474, 516, 536, 542, 553, 572, 576-578, 603). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 38 template variables present; the marker_#_* and qualitative_item_# repeat placeholders are correctly expanded to 11 marker rows and 6 qualitative items. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Structural diff against the template shows changes only inside the metadata block and the addressed spans; website="evidence_review", website="audit" and website="full_review" spans, the CSS block and the footer are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section is empty; the ER High benefit and High risk tiers carry explanatory prose, handled under 12.5 / 13.5. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | “Standard protocol”, “Single versus split dosing”, “Dose-ranging alternative” are the ER’s verbatim bold labels (ER lines 346, 348, 360). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | All 11 marker names are verbatim ER table entries; time-cell labels “Nail breakage”, “Hair shedding”, “Skin measures” are ER phrases (ER lines 385, 407). |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji code points present; the ER’s “⚠️ Conflicted” marker is correctly not carried over. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed to its per-section budget: benefits and risks collapse each ER tier into one semicolon list, gate items are single facts, and no explanatory prose is carried over. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2-14, immediately after <!doctype html> on line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- line 3, closing --- line 13; the preamble text sits on line 2. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is repeated in the header or footer. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:02" is quoted, which is required because the value contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: solubilized_keratin_2026-0813-0600_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md badge version. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0813-0648. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the on-disk filename solubilized_keratin_2026-0813-0600_Opus_QRS.html. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified: all nine keys parse cleanly, no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Solubilized Keratin for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic with the ampersand encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Solubilized Keratin for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “08/13/2026”, the correct reformat of 2026-0813-0648. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”, matching the frontmatter. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header block (lines 415-428) is structurally identical to the template; the ER’s “Also known as” line is not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses ER Conclusion lines 478-480: what it is, what three months delivers, the funding limitation, and the biotin assay problem. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | Exactly 60 words (em-dash excluded), at the limit. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Definition → ER line 478; three-month outcomes → line 478; sponsor funding and no outside replication → line 478; minor harms and biotin assay interference → line 480. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “taken apart so the gut can absorb it”, “distorts common blood tests” are plain-language renderings of solubilization and immunoassay interference. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No author names, years or sample sizes appear. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No percentages or numeric effect estimates; “fewer hairs shed, harder nails” is directional only. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All seven items map to the ER “Populations who should avoid Solubilized Keratin” list (ER lines 315-322). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All six ER bullets are represented; the combined allergy bullet is split into two items (wool/lanolin/poultry/feather; fish/shellfish with marine collagen), losing nothing. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Seven <li> elements inside the stop_items span (lines 575-587). |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s “because” and “since” rationales (unbound phenylalanine, every trial excluded these groups) are stripped; no dash-trailing clauses remain. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “(cystathionine beta-synthase deficiency)”, “stage 4 or worse (eGFR below 30) on a protein-restricted diet, at protein-supplement doses”, “(copper-containing capsules)”, “under 18” all preserved. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in its contraindication list. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names six avoid-populations, and the section is correctly populated rather than empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All seven items map to the ER interaction bullets (ER lines 299-311). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All seven “Caution” bullets are carried; the eighth ER bullet (“Other interventions”) is correctly omitted since the ER states no interaction is known or expected. No overlap with the Contraindications gate. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Seven <li> elements inside the caution_items span (lines 595-612). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s mechanism and mitigation sentences and the Li et al., 2018 citation are all stripped; the ER’s em-dash example lists are normalized into parentheses. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Drug lists preserved throughout: “(doxycycline, minocycline, ciprofloxacin, levofloxacin)”, “(alendronate, risedronate)”, “(calcium carbonate, magnesium hydroxide, iron salts)”, “(zinc, selenium, multivitamins)”, “(N-acetylcysteine, whey protein, collagen peptides, methylsulfonylmethane)”, “(thyroid-stimulating hormone, troponin)”. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in its interaction list. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names seven such interactions, and the section is correctly populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells derive from ER Therapeutic Protocol (lines 346, 348, 356, 360). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Standard dose and duration, dosing pattern, and the dose-ranging alternative are the three decision-relevant levers; the remaining ER bullets are contextual (half-life, popularisers, sex differences) rather than actionable. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies more than three actionable aspects, so no set is unused. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans populated; values “500 mg/day for 90 days”, “Two capsules daily, with meals”, “1000 mg/day” all trace to ER lines 346, 360/356 and 348. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Nail, hair shedding and skin — exactly the three aspects the ER’s “Time to effect” bullet distinguishes (ER line 407). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Nail hardness carries the largest magnitude (90.0-96.8% vs 27.6% placebo, ER line 169), then hair shedding (34.4%, line 163), then skin (+11.1-17.0%, line 175). |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three distinct time-to-effect aspects, so no set is unused. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine spans populated; “Day 30”/”Day 30”/”Day 45” match ER line 407, and the subs draw on ER lines 366, 407 and 173. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect data, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Every listed item corresponds to an ER Expected Benefits sub-heading (ER lines 159-205). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present at lines 545, 548, 554, 560. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier is a bare semicolon list of the ER sub-headings; the ER’s Magnitude lines, mechanisms and citations are all stripped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any benefits item; the ER’s “⚠️ Conflicted” marker on hair shedding is also correctly dropped. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER states no benefit rests on high-quality evidence, and benefits_high carries style="display: none" (line 545) with no empty-state text on the sheet. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Every listed item corresponds to an ER Potential Risks & Side Effects sub-heading (ER lines 237-277). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present at lines 624, 627, 632, 639. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier is a bare semicolon list of ER sub-headings; the ER’s Magnitude figures (10 ng/mL biotin, 4% withdrawal, 40 mg zinc) are all stripped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any risks item. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER states no risk rests on high-quality evidence, and risks_high carries style="display: none" (line 624). |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | All rows come from the ER Monitoring Protocol & Defining Success biomarker table (ER lines 435-447). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 11 ER rows present in ER order: ferritin, TSH, free T4, serum zinc, serum copper, serum selenium, 25-hydroxyvitamin D, complete blood count, plasma homocysteine, eGFR, hair pull test. Targets and “Why” text match the ER. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 809-813 reproduce the ER cadence from line 433: baseline, photographs and nail count at 45 and 90 days, thyroid and ferritin recheck at three months if borderline, six to twelve months thereafter. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All six items come from the ER “Qualitative markers worth tracking” list (ER lines 451-456). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER qualitative markers present and verbatim: wash-day shed count, split/chipped/broken nail count, subjective nail hardness, hair shine and manageability, skin smoothness and hydration, digestive comfort in the first two weeks. |
Issues 13/08/2026 07:14
Pass rate 100.00%. No issues found.
Issues 13/08/2026 07:07
- 1.1 — Ambiguous “past 60” in nail timing:
time_1_sub(QRS line 505) states “nail plates grow more slowly past 60” alongside “Day 30” and “day 90” values, so the threshold reads as a day count; the ER (line 366) means age 60.
Fixes 13/08/2026 07:07
- 1.1 — Nail timing threshold clarified: Changed
time_1_subfrom “nail plates grow more slowly past 60” to “nail plates grow more slowly past age 60”, so the threshold reads as an age rather than a day count, matching the ER.
Issues 13/08/2026 07:00
- 1.3 — Unhedged harms claim in At-A-Glance: [at_a_glance] (line 437) asserts “Harms are minor”, dropping the ER
Conclusion’s hedge “Harms recorded so far are minor” (ER line 480) and contradicting the ER’s High-risk tier statement that trials are “too small and too short” with “no post-marketing surveillance dataset” (ER line 233).
Fixes 13/08/2026 07:00
- 1.3 — Restored ER hedge on harms: Changed [at_a_glance] from “Harms are minor” to “Harms recorded so far are minor”, matching the ER
Conclusion; “cosmetic effects, not life-extending ones” was trimmed to “cosmetic, not life-extending” to keep the summary within the 60-word limit.
Issues 13/08/2026 06:55
- 11.4 — Skin time-cell sub describes nails: [time_3_sub] (line 530) sits under the “Skin measures” / “Day 45” cell but its explanatory text — “nail plates grow more slowly past 60, so an assessment window beyond 90 days is reasonable” — is drawn from the ER’s
Age considerationsbullet and describes the nail endpoint, not skin.
Fixes 13/08/2026 06:55
- 11.4 — Skin time-cell sub describes nails: Moved the nail-plate growth and assessment-window clause out of [time_3_sub] into [time_1_sub], where it belongs with the “Nail breakage” endpoint, and replaced [time_3_sub] with skin-specific ER content (“Skin hydration, elasticity and wrinkle depth moved by day 45; the trials ran 90 days, so durability beyond that is unknown”).